Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats

Diabetes

Volumn 51, Issue 10, 2002, Pages 2903-2910

  Cline, Gary W ^a   Johnson, Kirk ^b   Regittnig, Werner ^a   Perret, Pascale ^a   Tozzo, Effie ^b   Xiao, Linda ^b   Damico, Christine ^b   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHIR 98023; CHIR 99021; GLUCOSE; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN LIVER LEVEL; GLYCOGEN MUSCLE LEVEL; GLYCOGEN SYNTHESIS; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STRUCTURE ANALYSIS;

EID: 0036789185     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.10.2903     Document Type: Article

References (47)

1. Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Bogardus C: Glucose storage is a major determinant of in vivo "insulin resistance" in subjects with normal glucose tolerance. J Clin Endocrionol Metab 62:922-977, 1986
2. 13C nuclear magnetic resonance spectroscopy. N Engl J Med 332:223-228, 1990
3. Bogardus C, Lillioja S, Stone K, Mott D: Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 73:1185-1190, 1984
4. Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H: Reduced glycogen synthase activity in skeletal muscle from obese patients with and with type 2 (non-insulin-dependent) diabetes mellitus: Diabetologia 34: 239-245, 1991
5. Wright KS, Beck-Nielsen H, Kolterman OG, Mandarino LJ: Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM. Diabetes 37:436-440, 1988
6. Kelley DE, Mintun MA, Watkins SC, Simoneau J-A, Jadali F, Fredrickson A, Beattie J, Theriault R: The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705-2713, 1996
7. Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM: Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107-1113, 1998
8. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate: evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 89:1069-1075, 1992
9. Bonadona RC, Del Prato S, Bonora E, Saccomani MP, Gulli G, Natali A, Frascerra S, Pecori N, Ferrannini E, Bier D, Cobelli C, DeFronzo RA: Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 45:915-925, 1996
10. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Insucchi S, Dresner A, Rothman DL, Shulman GI: Impaired glucose transport as a cause of degraded insulin stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246, 1999
11. Williams KV, Price JC, Kelley DE: Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance: a dose-response assessment using positron emission tomography. Diabetes 50:2069-2079, 2001
12. Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P: Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur J Biochem 107:529-537, 1980
13. Plyte S, Hughes K, Nikolakaki E, Pulverer B, Woodgett JR: Glycogen synthase kinase-3: functions in oncogenesis and development. Bicohiem Biophys Acta 1114:147-162, 1992
14. Sutherland C, Leighton IA, Cohen P: Inactivation of glycogen synthase-3β by phosphorylation: new kinase connection in insulin and growth-factor signalling. Biochem J 296:15-19, 1993
15. Rodriguez-Gil JE, Guinovart JJ, Bosch F: Lithium restores glycogen synthesis from glucose in hepatocytes from diabetic rats. Arch Biochem Biophys 301:411-415, 1993
16. Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE, Birnbaum MJ: The role of glycogen synthase kinase 3β in insulin-stimulated glucose metabolism. J Biol Chem 274:17934-17940, 1999
17. Tabata I, Schluter J, Gulve EA, Holloszy JO: Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes 43:903-907, 1994
18. Furnsinn C, Noe C, Herdlicka R, Roden M, Nowotny P, Leighton B, Waldhausl W: More marked stimulation by lithium than insulin of the glycogenic pathway in rat skeletal muscle. Am J Physiol 273:ES14-E520, 1997
19. Orena SJ, Torchia AJ, Garofalo RS: Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 275:15765-15772, 2000
20. Nikoulina SE, Ciaraldi TP, Carter L, Cha B-S, Johnson K, Henry RR: Role of glycogen synthase kinase-3 in regulation of glucose metabolism and insulin action in human skeletal muscle cells (Abstract). Diabetes 49 (Suppl. 1):A275, 2000
21. Ring D, Johnson K, Henricksen E, Nuss J, Goff D, Kinnick T, Ma S, Reeder J, Samuels I, Slabiak T, Wagman A, Wernette-Hammond ME, Harrison SD: Glycogen synthase kinase-3 (GSK3) inhibitors potentiate glucose tolerance and muscle glycogen synthase acivity and glucose uptake in the Zucker Diabetic Fatty (ZDF) rat (Abstract). Diabetes 50 (Suppl. 2):A279, 2001
22. Lochhead PA, Coghlan M, Rice SQJ, Sutherland C: Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression. Diabetes 50:937-946, 2001
23. Rossetti L, Smith D, Shulman GI: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515, 1987
24. 13C-Nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus. J Clin Invest 94:2369-2376, 1994
25. Kraegen EW, James DE, Jenkins AB, Chisholm DJ: Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362, 1985
26. 14C-glucose. Anal Biochem 125:486-499, 1968
27. Nuttall FQ, Gannon MC: An improved assay for hepatic glycogen synthase in liver extracts with emphasis on synthase R. Anal Biochem 178:311-319, 1989
28. Pierson, RN Jr, Price DC, Wang J, Jain RK: Extracellular water measurements: organ tracer kinetics of bromide and sucrose in rats and man. Am J Physiol 235:F254-F264, 1978
29. Tang H, Vasselli JR, Wu EX, Boozer CN, Gallagher D: High-resolution magnetic resonance imaging tracks changes in organ and tissue mass in obese and aging rats. Am J Physiol Regul Integr Comp Physiol 282:R890-R899, 2002
30. Abumrad NN, Cherrington AD, Williams PE, Lacy WW, Rabin D: Absorption and disposition of a glucose load in the conscious dog. Am J Physiol 242:E398-E406, 1982
31. Shulman GI, Rothman DL, Smith D, Johnson CM, Blair JB, Shulman RG, DeFronzo RA: Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy. J Clin Invest 76:1229-1236, 1985
32. Shulman GI, Rossetti L, Rothman DL, Blair JB, Smith D: Quantitative analysis of glycogen repletion by nuclear magnetic resonance spectroscopy in the conscious rat. J Clin Invest 80:387-393, 1987
33. Cline GW, Shulman GI: Quantitative analysis of the pathways of glycogen repletion in periportal and perivenous hepatocytes in vivo. J Biol Chem 266:4094-4098, 1991
34. Cline GW, Greenawalt K, Shulman GI: Enhanced gluconeogenic flux of hepatic glycogen repletion by a phenacyl imidazolium compound, in vivo. Acta Diabetol 30:70-72, 1993
35. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE: Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects: biochemical and molecular mechanisms. J Clin Invest 98:1231-1236, 1996
36. Ren J-M, Marshall BA, Gulve EA, Gao J, Johnson DW, Holloszy JO, Mueckler MM: Evidence from transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal muscle. J Biol Chem 268:16113-16115, 1993
37. Ren J-M, Marshall BA, Mueckler MM, McCaleb M, Amatrda JM, Shulman GI: Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J Clin Invest 95:429-432, 1995
38. Lawrence JC Jr, Roach PJ: New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 46:541-547, 1997
39. Manchester J, Skurat AV, Roach P, Hauschka SD, Lawrence JC Jr: Increased glycogen accmulation in transgenic mice overexpressing glycogen synthase in skeletal muscle. Proc Natl Acad Sci USA 93:10707-10711, 1996
40. Wilson JE: Regulation of mammalian hexokinase activity. In Regulation of Carbohydrate Metabolism. Beitner R, Ed., Boca Raton, FL, CRC Press, 1984, p. 45-85
41. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI: Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 101: 1203-1209, 1998
42. Maggs DB, Burant CF, Buchanan TA, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 128:176-185, 1998
43. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI: Increased rate of gluconeogenesis in type II diabetes mellitus. J Clin Invest 90:1323-1327, 1992
44. DeFronzo RA: Lilly Lecture 1987: the triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
45. Pagliassotti MJ, Myers SR, Moore MC, Neal DW, Cherrington AD: Magnitude of negative arterial-portal glucose gradient alters net hepatic glucose balance in conscious dogs. Diabetes 40:1659-1668, 1991
46. Galassetti P, Shiota M, Zinker B, Wasserman DH, Cherrington AD: A negative arterial-portal glucose gradient decreases skeletal muscle glucose uptake in the conscious dog. Am J Physiol 275: E101-E111, 1998
47. Cherrington AD: Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214, 1999